Detail akcie Bio Blast Pharma online

Business Summary: Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Enlivex Therapeutics Ltd revenues was not reported. Net loss decreased 48% to $15M. Lower net loss reflects Research and development expenses - Bala decrease of 51% to $6.1M (expense), Loss on disposal group of assets held fo decrease of 92% to $352K (expense), Labor & Related Expenses in R&D decrease of 42% to $3.1M (expense).